Senti Biosciences (SNTI) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing cell and gene therapies using synthetic biology gene circuits for enhanced precision and control in targeting diseases, primarily cancer.

• Lead program SENTI-202 targets hematologic cancers, showing complete remissions in initial clinical data; pipeline includes off-the-shelf CAR-NK cells and collaborations with Roche/Spark and Bayer/BlueRock.

• Strategic collaboration in China for SENTI-301A to treat solid tumors, with first patient dosed in late 2024.

Financial performance and metrics

• Raised approximately $47.6 million in a December 2024 private placement (PIPE) through Series A Preferred Stock and accompanying warrants.

• Recurring losses, negative cash flows from operations, and an accumulated deficit raise substantial doubt about ability to continue as a going concern, as noted by auditors.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling securityholders; proceeds from warrant exercises, if any, will be used for working capital, general corporate purposes, R&D, and advancing SENTI-202.